Chemosensitivity Testing System: HepaHope Approach
The Chemosensitivity Testing System further leverages the inherent versatility of HepaHope's core bioreactor technology. In assessing market opportunities for additional medical applications beyond the HepaPheresis™ System, HepaHope focused on the field of cancer treatment, and particularly the area of chemosensitivity testing. With healthcare costs rising at alarming and unsustainable rates, the need for more cost-effective, accurate, efficient, and patient-friendly healthcare solutions has never been greater or more urgent.
Nowhere is that need more evident than in the areas of cancer treatment and chemosensitivity testing. HepaHope immediately recognized the unique potential of its core bioreactor technology to meet that need by its potential to provide a significantly more cost-effective and accurate means of obtaining critical patient data — data essential to prescribing an effective, accurate, patient-specific chemotherapeutic regimen to treat the disease.
HepaHope is convinced that at least 75% of all chemosensitivity and chemoresistivity testing could be enhanced by the use of the Chemosensitivity Testing System and its proprietary tissue culture technology. Accurately prescribing patient-specific dosage and multiple drug combinations is essential for achieving optimal therapeutic effects in cancer patients. When applied to tumor specimens in chemosensitivity testing, HepaHope's Chemosensitivity Testing System should provide the kind of accurate, reliable, and cost-effective data needed to aid therapists in achieving that goal.